Monetary Management Group Inc Bei Gene, Ltd. Transaction History

Monetary Management Group Inc

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 13, 2020	SELL	$115.78 - $208.34 $103,623 - $186,464	-895 Closed	0 $0
Q3 2019 Nov 12, 2019	BUY	$120.61 - $148.29 $23,518 - $28,916	195 Added 27.86%	895 $110,000
Q2 2019 Aug 13, 2019	BUY	$113.99 - $146.86 $79,793 - $102,802	700 New	700 $87,000

251

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $23.5B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Monetary Management Group Inc, based on Form 13F filings with the SEC.

Stay updated on Monetary Management Group Inc with notifications on news.